Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., ... announce its study " Sensitivity of a rapid point ... enhanced by its affinity for HIV gp41 IgM antibodies ... Virology.  This study highlights INSTI,s ability to detect early ... findings at the 8 th annual International AIDS ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... non-invasive hydration monitoring wearable early 2016. , The device, called the Halo ... proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid levels ...
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
Breaking Biology Technology:bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... 31, 2008 at 11:00 a.m. EDT, NEW ... China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin ... branded,bio-pharmaceutical products in China, today announced it will ... on Monday 31, 2008. In,conjunction, the Company will ...
... International,Corporation (Nasdaq: PRXL ) will release Third Quarter ... after the close of the stock,market. The announcement will ... on the PR Newswire website at http://www.prnewswire.com ... live webcast at 10:00 a.m. EDT,on Thursday, April 24, ...
... Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical company, announced ... and Development, is,scheduled to present at Cambridge ... March 28st at 1:35 p.m. PST at ... Dr. Rao will focus on,considerations that are ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results 2PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call 2
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 2011) Proving that technological entrepreneurship can have ... fields, renowned innovator, materials scientist and applied physicist ... recipient of the 2011 $500,000 Lemelson-MIT Prize. Rogers, ... products integral to human health, fiber optics, semiconductor ...
... A new study provides support for Darwin,s hypothesis ... more closely related species than those distantly related. ... study contains the strongest direct experimental evidence yet ... species extinction occurred more frequently and more rapidly ...
... rapidly spreading amphibian disease, has reached a site near ... the entire mountainous neotropics to be free of the ... Rescue and Conservation Project, a consortium of nine U.S. ... of frogs in imminent danger of extinction. ...
Cached Biology News:Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 2Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 3Materials scientist and entrepreneur Dr. John Rogers awarded $500,000 Lemelson-MIT Prize 4New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3
Request Info...
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Biology Products: